Hinge Health
Hinge Health's revenue rose 50.6% to $588 million in fiscal 2025. Its operating margin was −92.9%, down from −8.2% a year earlier. Free cash flow was $171 million, up 256.0%. It paid out $65 million in dividends and buybacks, 38% of free cash flow. The diluted share count rose 302.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Hinge Health does
Hinge Health sells a digital program for muscle and joint (MSK) care, covering injuries, chronic pain and recovery after surgery. Members use motion-tracking software and a wearable device that gives electrical nerve stimulation, and a care team of licensed physical therapists, physicians and health coaches, supported by AI, monitors the program.
Its customers are mainly self-insured employers, including public-sector employers such as city governments and labor unions. It also serves health plans' fully insured and Medicare Advantage members, and federal insurance plans. It sells through its own sales force and through partners such as health plans and benefit managers.
Hinge Health is usually the only digital MSK provider offered to a client's covered people, and its average contract term was three years at the end of 2025. It earns recurring revenue for the life of each contract, and it aims to reduce its clients' costs. It has a limited operating history.
Its biggest risks, as it describes them
- It may not carry out its growth plans and strategies.
- Clients may not renew their contracts, or may renew on worse terms.
- It may fail to keep existing members or add new ones.
- It pays upfront costs for each client and partner and may not recover them if relationships don't grow.
- Competitors and other advances in treating joint and muscle conditions could limit its acceptance.
Income statement
Hinge Health lost money in fiscal 2025: a net loss of $528 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 235 | 467 | 364 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | — | 2.3x | 1.5x |
| Quick ratio | — | 2.3x | 1.4x |
Cash flow
Projections
Project Hinge Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Hinge Health says to expect
- Fourth quarter 2026: revenue
We expect revenue to be between $249 million and $251 million, reflecting year-over-year growth of 46% at the midpoint.
- Full year 2026: revenue
We are raising our revenue guidance to be between $879 million and $881 million, reflecting year-over-year growth of 50% at the midpoint.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Hinge Health shares on the open market, and 10 insiders sold $546.0 million, $437.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | Gabriel M.I. MecklenburgDirector | Sold plan | 200,000 | $122.41 | $24.5 million | Form 4 |
| Nov 10, 2026 | James BudgeChief Financial Officer | Sold plan | 35,907 | $121.62 | $4.4 million | Form 4 |
| Sep 21, 2026 | James PursleyPresident | Sold plan | 33,000 | $94.13 | $3.1 million | Form 4 |
| Sep 14, 2026 | Gabriel M.I. MecklenburgDirector | Sold plan | 150,000 | $93.22 | $14.0 million | Form 4 |
| Sep 11, 2026 | Gabriel M.I. MecklenburgDirector | Sold plan | 250,000 | $88.97 | $22.2 million | Form 4 |
| Sep 10, 2026 | Daniel Antonio PerezCEO & Co-Founder, Director, 10% owner | Sold plan | 250,000 | $89.45 | $22.4 million | Form 4 |
| Sep 10, 2026 | James BudgeChief Financial Officer | Sold plan | 55,561 | $89.45 | $5.0 million | Form 4 |
| Aug 21, 2026 | James PursleyPresident | Sold plan | 33,000 | $88.05 | $2.9 million | Form 4 |
| Aug 20, 2026 | Kristina M LeslieDirector | Sold | 1,200 | $88.23 | $105,876 | Form 4 |
| Jul 9, 2026 | Insight Venture Associates X L.P.10% owner | Sold plan | 181,499 | $90.20 | $16.4 million | Form 4 |
| Jul 7, 2026 | Insight Venture Associates X L.P.10% owner | Sold plan | 244,672 | $90.23 | $22.1 million | Form 4 |
| Jul 1, 2026 | Gabriel M.I. MecklenburgDirector | Sold plan | 83,334 | $85.05 | $7.1 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | 45.6% | 79.6% |
| Altman Z'' | −1.37 | −7.51 |
| Accruals ratio | — | −98.7% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | — | Fail |
| Cash from operations is positive | Pass | Pass |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put Hinge Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Hinge Health | FY25 | 50.6% | −92.9% | 29.0% | — | — | — | |
| Doximity | FY26 | 13.1% | 33.3% | 50.6% | 91.3% | −3.3x | 4 | Compare |
| Phreesia | FY26 | 14.5% | −1.4% | 14.1% | −2.2% | −2.6x | 6 | Compare |
| Certara | FY25 | 8.8% | 5.0% | 22.6% | 0.9% | 1.1x | 5 | Compare |
| Waystar | FY25 | 16.5% | 22.7% | 25.8% | 3.5% | 3.6x | 5 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 293 | 390 | 588 |
| Revenue growth | — | 33.4% | 50.6% |
| Gross profit | 194 | 300 | 468 |
| Research and development | 110 | 101 | 368 |
| Operating income | −130 | −32 | −546 |
| Net income | −108 | −12 | −528 |
| Diluted EPS (US$) | −8.31 | −0.88 | −7.77 |
| Diluted shares (millions) | 13 | 14 | 55 |
| Cash flow | |||
| Cash from operations | −64 | 49 | 171 |
| Capital expenditure | 2 | 1 | 1 |
| Free cash flow | −66 | 48 | 171 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 65 |
| Acquisitions | 0 | 0 | 4 |
| Stock-based compensation | 2 | 1 | 643 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 235 | 467 | 364 |
| Debt incl. finance leases | — | — | — |
| Total assets | — | 673 | 745 |
| Total liabilities | — | 257 | 366 |
| Shareholders' equity | −424 | −435 | 179 |
| Margins and ratios | |||
| Gross margin | 66.3% | 76.8% | 79.7% |
| Operating margin | −44.6% | −8.2% | −92.9% |
| Net margin | −36.9% | −3.1% | −89.9% |
| Free cash flow margin | −22.5% | 12.3% | 29.0% |
| Rule of 40 (growth + FCF margin) | — | 45.6% | 79.6% |
| Return on capital | — | — | — |
| Return on equity | — | — | — |
| Return on assets | — | — | −74.5% |
| Net debt to EBITDA | — | — | — |